Skip to main content
. 2013 May 27;34(31):2453–2463. doi: 10.1093/eurheartj/eht187

Figure 2.

Figure 2

Mean change from baseline to visit 4 (day 15 ± 1) and the mean of visit 6 (day 22) and visit 7 (day 29 ± 2) in serum potassium concentration in patients receiving BAY 94-8862, placebo, or spironolactone in the full analysis set of part B of ARTS. *P < 0.05 between the BAY 94-8862 dose group and the placebo group at visit 6/7; †P < 0.05 between the BAY 94-8862 dose group and the spironolactone group at visit 6/7. Significance of visit 4 data was not analysed. b.i.d., twice daily; q.d., once daily.